Acetylsalicylic Acid Tablets
Dosage
Packaging
What is Acetylsalicylic Acid?
Active Ingredients: Acetylsalicylic Acid
Acetylsalicylic Acid Tablets are a nonsteroidal anti-inflammatory (NSAID) drug that is used to relieve mild to moderate pain. This medicine is used to treat symptoms of generalized aches and pain, rheumatoid arthritis, angina, fever, headaches and migraines, and myocardial infarction.
Acetylsalicylic acid is also known by the name of aspirin. This drug is classified as a salicylate, which has analgesic, antipyretic and anti-inflammatory properties. It can also be used as an antiplatelet because of the active ingredient's ability to interrupt the formation of bodily thromboxane and platelet aggregation.
AdvaCare Pharma is a trusted global distributor of Acetylsalicylic Acid Tablets. Our company offers a wide selection of high-quality and cost-effective medical products. These products are manufactured in factories located in China, India, and the USA. These facilities are regularly inspected to ensure they meet GMP certification requirements.
Why are we a leading Aspirin manufacturer?
As a reputable Aspirin manufacturer, also referred to as Acetylsalicylic Acid, we are dedicated to ensuring that GMP guidelines and standards strictly apply to the manufacture of our entire range of 200+ pharmaceutical treatments in tablet dosage form.
AdvaCare Pharma is an American pharmaceutical company committed to the manufacture of high-quality, affordable pharmaceuticals for a global market. The extensive international network that we partner with includes pharmaceutical distributors, hospitals, pharmacies, and a variety of other medical institutions. Our vision is to manufacture Aspirin Tablets, and other quality-assured oral solid treatments, that get into the hands of those that need them most.
Uses
What is Acetylsalicylic Acid used for?
Acetylsalicylic acid is also used for its antiplatelet effects in selected cardiovascular conditions, including secondary prevention following myocardial infarction and in patients at risk of recurrent atherothrombotic events.
In patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), aspirin is commonly used as part of dual antiplatelet therapy (DAPT) together with a P2Y12 inhibitor. The 2025 ACC/AHA guideline for acute coronary syndromes recommends aspirin plus an oral P2Y12 inhibitor as the default DAPT strategy for many patients with ACS who are not at high bleeding risk. Treatment selection and duration should be individualized according to the clinical situation, ischemic risk, bleeding risk, and applicable local guidelines.
How are Acetylsalicylic Acid Tablets used?
This medication is intended to be taken orally. Each tablet should be taken with a full glass of water or at meal time, in order to reduce gastrointestinal side effects.
How should Acetylsalicylic Acid Tablets be stored?
This medication should be kept in its original packaging until use. The tablets should be stored in a dry location at room temperature. Do not use the tablets past their expiry date. If a tablet has a scent similar to strong vinegar, it should be discarded.
What dose should be taken?
Adult Dosing Dosage may vary based on different medical indications:
- For pain or fever, the usual dose is 300-600mg taken every 4-6 hours, as needed. The maximum dosage is 4g per day.
- For acute coronary syndrome, the usual dose is 162-325mg taken once per day.
- For MI prevention, the usual dose is 81-325mg taken once per day.
- For TIA/thromboembolic stroke prevention, the usual dose is 75-325mg taken once per day.
- For arthritis (off-label), the usual dose is 2.6-5.4g per day, divided and taken every 4-6 hours.
- For preeclampsia prevention (off-label), the usual dose is 81mg, taken once per day. Treatment should begin at 12-28 weeks of gestation and continue until delivery.
- For rheumatic fever (off-label), the usual dose is 5-8g per day, divided and given every 4-6 hours for 1-2 weeks. Then the dose should be tapered over the following 2-8 weeks.
Renal Dosing The guidelines for adult patients with renal impairment are as follows:
- CrCl < 10: The use of this medicine should be avoided.
- HD: No adjustment is necessary on dialysis days, and the medicine should be given after dialysis. No supplement is required.
- PD: The use of this medicine should be avoided.
Hepatic Dosing There are no defined guidelines for the use of this drug in patients with hepatic impairment.
Pediatric Dosing The recommendations for dosage adjustments for children are as follows:
- For pain or fever, the usual dose is 10-15mg/kg per dose, given every 4-6 hours as needed. The maximum dosage is 60-80mg/kg per day.
- For juvenile idiopathic arthritis (off-label), the usual dose is 60-100mg/kg per day, divided and taken every 6-8 hours. The starting dose should be 60mg/kg per day, divided and taken every 6-8 hours. Then the dose may be increased by 10-20mg/kg per day every 5-7 days. The maximum dosage is 100mg/kg per day.
- For Kawasaki disease (off-label), the usual dose is 80-100mg/kg per day, divided and given every 6 hours. After the resolution of fever, the dose should be decreased by 3-5mg/kg per dose each day. The total duration of treatment is 8 weeks.
- For the prevention of thrombotic events (off-label), the usual dose for children over 2 years old is 1-5mg/kg per dose, taken once per day. The maximum dosage is 325mg per day. It is advised to consult local guidelines or institution protocols for information on the appropriate use of this medicine in pediatrics.
Renal Dosing for children The guidelines for pediatric patients with renal impairment are as follows:
- CrCl < 10: The use of this medicine should be avoided.
- HD: No adjustment is necessary on dialysis days, and the medicine should be given after dialysis. No supplement is required.
- PD: The use of this medicine should be avoided.
Hepatic Dosing for children There are no defined guidelines for the use of this drug in patients with hepatic impairment.
Refer to a doctor or pharmacist for guidelines on dosage. Do not exceed what they advise.
Who can use Acetylsalicylic Acid?
Acetylsalicylic Acid Tablets can be given to adults and children, but caution is advised for specific groups of patients.
Pregnant Low-dose Acetylsalicylic Acid is appropriate to use for pregnant women. The benefits must be weighed against the risks of the use of full-dose Acetylsalicylic Acid in women at 20-29 weeks gestation. If used, it is advised to limit the dose and duration and monitor amniotic fluid if the pregnant woman is using it longer than 48 hours.
Full-dose Acetylsalicylic Acid should be avoided starting at 30 weeks gestation. Based on human data with full dosage, there is a risk of fetal harm that begins at 20 weeks gestation, including renal dysfunction and oligohydramnios, a risk of premature fetal ductus arteriosus closure beginning at 30 weeks, and an increased risk of excessive blood loss during labor and delivery. These risks have not been reported with low-dose Acetylsalicylic Acid use.
Breastfeeding When used as an analgesic, the benefits of full-dose acetylsalicylic acid must be weighed against the risks. It is advised to avoid full-dose treatment if the nursing infant is suffering from a viral infection. Though there is inadequate human data, there is a possible risk of bleeding, thrombocytopenia, and metabolic acidosis. No human data is available to properly assess the effects of this drug on milk production.
Children Though the use of this drug is considered safe in children over 3 years old, it is important to note that Acetylsalicylic Acid Tablets should not be given to children who have symptoms of a viral infection like flu or chickenpox. The use of Acetylsalicylic Acid in children has been linked to Reye’s syndrome, particularly in children who have had a recent viral infection.
Geriatric The use of Acetylsalicylic Acid is generally considered safe for elderly patients but may be more likely to experience adverse effects. It should be noted that according to recent studies, this population has up to a 20% increased risk of anemia.
What does recent research show about aspirin after TAVI?
Antithrombotic treatment after transcatheter aortic valve implantation (TAVI) continues to evolve. The 2025 ESC/EACTS Guidelines for valvular heart disease recommend low-dose aspirin after TAVI for patients who do not otherwise require oral anticoagulation and do not recommend routine oral anticoagulation solely because TAVI has been performed.
The 2026 ACASA-TAVI randomized clinical trial evaluated 360 adults aged 65–80 years after TAVI and compared 12 months of factor Xa inhibitor anticoagulant monotherapy with acetylsalicylic acid monotherapy. CT-detected hypoattenuated leaflet thickening (HALT), a marker of subclinical valve-leaflet thrombosis, occurred in 16.2% of participants assigned to anticoagulation and 28.6% assigned to acetylsalicylic acid. Anticoagulation was also noninferior for the trial's composite safety endpoint of bleeding, thromboembolic events, or death.
These findings are important new clinical evidence, but they do not by themselves establish a new universal antithrombotic regimen after TAVI. The study involved a selected age group, was relatively small, and primarily evaluated imaging-detected subclinical leaflet thrombosis. Post-TAVI treatment should therefore continue to follow applicable clinical guidelines and individualized specialist assessment.
Is aspirin still used immediately after PCI for STEMI?
Aspirin remains an important component of antiplatelet treatment in many patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
The 2026 PREMIUM randomized trial investigated whether aspirin could be omitted from the beginning of treatment by comparing prasugrel monotherapy with aspirin-plus-prasugrel DAPT. Prasugrel monotherapy did not demonstrate noninferiority to DAPT for the composite outcome of death, stroke, or myocardial infarction at 12 months.
The findings therefore do not support routine omission of aspirin from the outset of antiplatelet treatment after primary PCI for STEMI under the conditions studied. However, the optimal duration and composition of antiplatelet therapy may vary according to bleeding risk, ischemic risk, accompanying medications, local treatment guidelines, and individual patient factors.
Other warnings
If tinnitus develops, therapy with Acetylsalicylic Acid should be discontinued.
As there is an increased risk of bleeding associated with this medicine, it is advised to express caution for those with conditions such as anemia, GI malabsorption, peptic ulcer history, gout, liver or kidney disease, vitamin K deficiency, alcoholism, renal calculi, thyrotoxicosis, hypochlorhydria, or hypoprothrombinemia.
Side Effects
As with all pharmaceuticals, some unwanted effects can occur from the use of Acetylsalicylic Acid Tablets.
Common side effects include, but may not be limited to:
- upset stomach
- heartburn
- drowsiness
- mild headache
Seek medical attention if the following develop:
- ringing in the ears
- confusion or hallucinations
- rapid breathing
- seizure
- severe nausea or vomiting
- stomach pain
- bloody or tarry stools
- coughing up blood
- fever lasting longer than 3 days
- swelling or pain lasting longer than 10 days
For a comprehensive understanding of all potential side effects, consult a medical professional.
If any symptoms persist or worsen, or you notice any other symptoms, please call your doctor immediately.
Precautions
Do NOT use Acetylsalicylic Acid (Aspirin) Tablets if:
- You are allergic to any of the ingredients.
- You have ever had an asthma attack or severe allergic reaction taking aspirin or an NSAID.
- You have a history of stomach bleeding or intestinal bleeding.
- You have a bleeding disorder such as hemophilia.
Before treatment, consult your doctor regarding any medications you are taking to address potential drug interactions.Some medications may need to be changed or switched due to increased risks of side effects. Some known interactions include NSAIDs (ibuprofen, ketoprofen, indomethacin, meloxicam, mefenamic acid, naproxen, etc.) antibiotics (e.g. amikacin), mifepristone, ramipril, and diuretics (e.g. acetazolamide). This is not a complete list.
This drug is contraindicated with abrocitinib, dichlorphenamide, ketorolac, influenza nasal vaccine (live), and varicella vaccine (live). Some medications may need to be changed or switched due to an increased risk of side effects.
This medication may not be suitable for people with certain conditions, so it is important to consult with a doctor if you have any health conditions.
Acetylsalicylic Acid Tablets are contraindicated with the following conditions: asthma (ASA-induced, NSAID-induced), urticaria (ASA-induced, NSAID-induced), GI ulcers with bleeding, hemorrhoids, hemorrhagic diathesis, nasal polyps due to asthma, sarcoidosis, thrombocytopenia, ulcerative colitis, hemophilia G6PD deficiency, uncontrolled hypertension, CrCl < 10 in patients not on hemodialysis, and peritoneal dialysis.
References
Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant: The ACASA-TAVI Randomized Clinical Trial
The ACASA-TAVI randomized clinical trial evaluated anticoagulant monotherapy compared with acetylsalicylic acid monotherapy following transcatheter aortic valve implantation (TAVI).
In 360 adults aged 65–80 years, CT-detected hypoattenuated leaflet thickening at 12 months occurred less frequently with factor Xa inhibitor anticoagulation than with acetylsalicylic acid. Anticoagulation also met the study's noninferiority criterion for the composite safety endpoint of bleeding, thromboembolic events, or all-cause death.
The findings provide new evidence concerning post-TAVI antithrombotic therapy, but the study does not independently establish a new universal treatment recommendation.
2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
The 2025 ESC/EACTS Guidelines for valvular heart disease provide contemporary recommendations for antithrombotic therapy following TAVI.
For patients without another indication for oral anticoagulation, the guideline recommends low-dose acetylsalicylic acid for 12 months after TAVI and does not recommend routine oral anticoagulation solely following TAVI. These recommendations provide important clinical context for interpreting newer evidence such as ACASA-TAVI.
Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI – PREMIUM Trial
The PREMIUM randomized trial evaluated whether aspirin could be omitted from the beginning of treatment in patients with STEMI undergoing primary PCI.
Prasugrel monotherapy did not demonstrate noninferiority to aspirin-plus-prasugrel dual antiplatelet therapy for the composite endpoint of death, stroke, or myocardial infarction at 12 months. The findings therefore did not support routine upfront aspirin omission under the treatment conditions evaluated in the trial.
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
The 2025 ACC/AHA guideline for acute coronary syndromes provides evidence-based recommendations for the treatment of patients with STEMI, NSTEMI, and other acute coronary syndromes.
The guideline identifies dual antiplatelet therapy with aspirin and an oral P2Y12 inhibitor as the default strategy for many patients with ACS who are not at high bleeding risk, while recognizing that antiplatelet strategies may be modified according to individual bleeding and ischemic risk.
